App Suite 2 is the second release in a series of planned App Suite releases, developed to provide automated live-cell studies to researchers worldwide in an unprecedented user-friendly workflow, using PHI’s HoloMonitor-technology.
By reason of chairman Klas Cramborn’s death, the Board of Directors of Phase Holographic Imaging (PHI) has decided to appoint Mats Lundwall as acting chairman of the Board. “Klas has meant a lot to PHI’s development. With his strategic skills in combination integrity and humor Klas has led the Board in a very commendable way
System-c bioprocess, Aurogene and Labsoft have recently been appointed to respectively represent Phase Holographic Imaging (PHI) in France, Italy and Poland.
For the first time, sales during the past 12 months reached 5 MSEK. Since our previous report, much effort has gone into implementing the ambitious market expansion made possible by the capital acquisition this summer.
A major publicly traded life science tools company has entered a technology assessment agreement with Phase Holographic Imaging (PHI). The purpose of the agreement is to assess PHI’s Holo¬Monitor technology for cell biology applications, primarily within immuno-oncology.
In June 2018, Phase Holographic Imaging (PHI) and BioSpherix Medical entered a collaboration agreement, aiming to co-market the companies’ complementary product lines. BioSpherix develops and market advanced hermetically sealed cell incubators for the control and optimization of cell culture environments.
Scientists at the Holographic Imaging Cytometry Center of Excellence at University of California, San Francisco, study how normal skin cells transform into aggressive skin cancer. HoloMonitor M4 plays an important role in their research.
For the first time, sales during the past 12 months reached 5 MSEK. Since our previous report, much effort has gone into implementing the ambitious market expansion made possible by the capital acquisition this summer.
Baserat på PHI:s befintliga HoloMonitor-teknik, har institutionen för Immunteknologi vid Lunds Universitet och Phase Holographic Imaging (PHI) avtalat om att gemensamt utveckla nya metoder för 3‑dimensionell cellodling. Detta för att möta ett akut och snabbt växande behov av dessa metoder inom cancerforskningen.
Based on PHI’s current HoloMonitor technology, the Department of Immunotechnology at Lund University and Phase Holographic Imaging (PHI) recently agreed to jointly develop novel 3-dimensional cell culturing methods to meet the urgent need for such methods.